Ahmedabad, Gujarat, India, September 2025 — Zydus Group has announced the appointment of Tushar Shroff as its new Chief Financial Officer, marking his return to the organization in a leadership role. In this capacity, he will be responsible for steering the financial strategy of the group, optimizing capital structures, and supporting its ambitious growth in the global life-sciences sector.
Tushar brings with him an illustrious career spanning more than three decades in finance, corporate strategy, and M&A across pharmaceutical, technology, healthcare, and industrial sectors. Prior to this appointment, he briefly served as President of Zydus Lifesciences, further strengthening his deep association with the group. Before this, he held the role of Group Chief Financial Officer at STL – Sterlite Technologies Limited in Mumbai, where he successfully drove financial transformation and governance across a rapidly scaling global digital solutions company.
Earlier, he served as Group CFO at Intas Pharmaceuticals, a US$ 2.5 billion pharmaceutical group with presence across 80+ countries. In this role, Tushar was pivotal in capital structuring, investor relations, and strategic finance, ensuring sustainable growth backed by Sovereign Funds and Private Equity partners. His earlier tenure with Zydus Cadila as Senior Vice President – Corporate Finance further highlighted his expertise in treasury, corporate planning, investor relations, and outbound M&A. Over nine years, he led fund-raising initiatives exceeding US$ 1 billion through syndicated loans, structured innovative financing for R&D, and played a key role in consolidating the group’s formulation business, making it future-ready for large-scale inorganic growth.
Prior to this, he worked as Chief Finance Officer at SCHOTT Kaisha Private Limited, a joint venture between SCHOTT Glass of Germany and Kaisha, where he established robust SOPs, implemented costing systems, and negotiated ECB funding from KFW Germany for a greenfield project. At the Piramal Group, as General Manager – M&A, he was closely involved in shaping the in-organic growth strategy for the domestic formulation business, successfully closing acquisitions such as Cifixim and Anfortan brands from Khadelwal Laboratories, global product rights from PlasmaSelect AG in Germany, and Minrad’s inhalation anaesthetic business in the US.
His earlier leadership roles include serving as Executive Director and CFO at Elster Metering Private Limited, where he managed post-acquisition integration after ABB’s divestment, established new manufacturing at Daman, migrated ERP platforms, and set up banking and tax structures. He began his professional journey at ABB India, where he rose through the ranks over nearly nine years from management trainee to Head of Finance and Business Area Controller. At ABB, he was instrumental in SAP R3 implementation, managing EPC contracts, optimizing duty structures, and supporting global financial reporting for the group’s NYSE listing.
Tushar’s career foundation was laid during his articleship with S.B. Billimoria & Co., followed by academic pursuits at Narsee Monjee College of Commerce and Economics, the Institute of Cost Accountants of India, and the Institute of Chartered Accountants of India, where he earned his FCA. He later enriched his leadership and strategic acumen through the General Management Program at the Indian Institute of Management, Ahmedabad, one of India’s premier business schools.
Through his extensive career, Tushar has consistently demonstrated financial stewardship, strategic foresight, and a strong ability to lead cross-border initiatives. His appointment as CFO of Zydus Group reflects the company’s confidence in his ability to strengthen its financial foundations as it advances its mission of delivering innovative healthcare solutions worldwide.
About Zydus Group
The Zydus Group, with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27,000 people worldwide and is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that transform lives.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
